Can cannabinoids be used to treat cancer?

When cannabinoids activate signaling pathways in cancer cells they can stimulate a cell death mechanism called apoptosis, unleashing a potent anti-tumor effect. Yet cannabinoids, which have also shown strong activity against human tumor tissue grown in animal models, have undergone minimal testing in patients. Their potential use as antitumor drugs and/or to boost the effectiveness of conventional cancer therapies is examined in an article published in The Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on JACM website.

In "A Review of the Therapeutic Antitumor Potential of Cannabinoids," coauthors Višnja Bogdanović and Jasminka Mrdjanović, Oncology Institute of Vojvodina (Sremska Kamenica, Serbia), and Ivana Borišev, University of Novi Sad (Serbia) present the results of a detailed survey of the medical and scientific literature focused on the effects of cannabinoids on signaling pathways involved in tumor cell proliferation and death. The researchers review the mechanisms of anticancer activity of cannabinoids, discuss the similarities and differences between exogenous (plant-derived) and endogenous cannabinoids, report on the clinical studies conducted to date to assess the anti-tumor effects of these compounds, and consider the possible adjuvant properties of cannabinoids in cancer treatment.

"Although medical cannabis is well-supported in the literature for symptom reduction from cancer treatment or the disease itself, there are many claims that cannabis can treat cancer itself," says Leslie Mendoza Temple, MD, ABOIM, University of Chicago Pritzker School of Medicine and Medical Director, Integrative Medicine Program. "So far, this is based on only a handful of small human studies, anecdote, or laboratory research. This article nicely summarizes some of the work done in the lab for an understanding of cannabis' potential anti-cancer mechanisms, while pointing to the paucity of human trials." Dr. Temple adds, "Federal rescheduling of cannabis is critical so we can study its effects in humans and determine cannabis' direct or indirect effects on cancer cells."

"The value of the review from Bogdanović, Mrdjanović, and Borišev is describing the evidence landscape that is generating claims for this very political herb," says JACM Editor-in-Chief John Weeks, Seattle, WA. He adds: "The evidence supports freeing researchers to provide us with more answers."

Bogdanović Višnja, Mrdjanović Jasminka, Borišev Ivana.
A Review of the Therapeutic Antitumor Potential of Cannabinoids.
The Journal of Alternative and Complementary Medicine. doi: 10.1089/acm.2017.0016.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...